GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:GENI - GG00BMF1JR16 - Common Stock
9.86 USD
-0.04 (-0.4%)
9.85 USD
-0.01 (-0.1%)
GENI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 132 industry peers in the Hotels, Restaurants & Leisure industry. No worries on liquidiy or solvency for GENI as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, GENI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year GENI has reported negative net income.
In the past year GENI had a positive cash flow from operations.
GENI had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: GENI reported negative operating cash flow in multiple years.
1.2 Ratios
GENI has a Return On Assets of -11.36%. This is amonst the worse of the industry: GENI underperforms 82.58% of its industry peers.
Looking at the Return On Equity, with a value of -16.49%, GENI is in line with its industry, outperforming 43.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.36% | ||
| ROE | -16.49% | ||
| ROIC | N/A |
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 21.98%, GENI is doing worse than 84.09% of the companies in the same industry.
GENI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
GENI has more shares outstanding than it did 1 year ago.
GENI has a better debt/assets ratio than last year.
2.2 Solvency
GENI has an Altman-Z score of 3.41. This indicates that GENI is financially healthy and has little risk of bankruptcy at the moment.
GENI has a Altman-Z score of 3.41. This is amongst the best in the industry. GENI outperforms 80.30% of its industry peers.
There is no outstanding debt for GENI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.41 |
ROIC/WACCN/A
WACC9.35%
2.3 Liquidity
GENI has a Current Ratio of 1.73. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
GENI has a better Current ratio (1.73) than 79.55% of its industry peers.
GENI has a Quick Ratio of 1.73. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
GENI's Quick ratio of 1.73 is amongst the best of the industry. GENI outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
GENI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.07%.
The Revenue has grown by 30.70% in the past year. This is a very strong growth!
GENI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.82% yearly.
EPS 1Y (TTM)-74.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320%
Revenue 1Y (TTM)30.7%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%38.34%
3.2 Future
GENI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.95% yearly.
The Revenue is expected to grow by 17.81% on average over the next years. This is quite good.
EPS Next Y30.31%
EPS Next 2Y56.84%
EPS Next 3Y44.95%
EPS Next 5YN/A
Revenue Next Year26%
Revenue Next 2Y21.49%
Revenue Next 3Y19.99%
Revenue Next 5Y17.81%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GENI. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 79.38 indicates a quite expensive valuation of GENI.
Based on the Price/Forward Earnings ratio, GENI is valued a bit more expensive than 66.67% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, GENI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 79.38 |
4.2 Price Multiples
GENI's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. GENI is more expensive than 62.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 430.55 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
GENI's earnings are expected to grow with 44.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.84%
EPS Next 3Y44.95%
5. Dividend
5.1 Amount
GENI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.86
-0.04 (-0.4%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)
Earnings (Next)
Inst Owners95.87%
Inst Owner Change-2.74%
Ins Owners8.59%
Ins Owner ChangeN/A
Market Cap2.50B
Revenue(TTM)604.52M
Net Income(TTM)-119.17M
Analysts83.2
Price Target15.33 (55.48%)
Short Float %10.26%
Short Ratio4.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1971.5%
Min EPS beat(2)-2756.23%
Max EPS beat(2)-1186.76%
EPS beat(4)1
Avg EPS beat(4)-1234.18%
Min EPS beat(4)-2756.23%
Max EPS beat(4)23.27%
EPS beat(8)2
Avg EPS beat(8)-582.96%
EPS beat(12)2
Avg EPS beat(12)-433.44%
EPS beat(16)4
Avg EPS beat(16)-321.25%
Revenue beat(2)1
Avg Revenue beat(2)1.03%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)3.82%
Revenue beat(4)1
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)3.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.53%
Revenue beat(12)4
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)1.27%
PT rev (1m)0.18%
PT rev (3m)2.45%
EPS NQ rev (1m)-0.7%
EPS NQ rev (3m)17.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-43%
Revenue NQ rev (1m)0.97%
Revenue NQ rev (3m)1.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 79.38 | ||
| P/S | 4.13 | ||
| P/FCF | 430.55 | ||
| P/OCF | 29.7 | ||
| P/B | 3.46 | ||
| P/tB | 10.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.47
EYN/A
EPS(NY)0.12
Fwd EY1.26%
FCF(TTM)0.02
FCFY0.23%
OCF(TTM)0.33
OCFY3.37%
SpS2.39
BVpS2.85
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.36% | ||
| ROE | -16.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.98% | ||
| FCFM | 0.96% |
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 118.97% | ||
| Cap/Sales | 12.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | 3.41 |
F-Score5
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)73.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-320%
EPS Next Y30.31%
EPS Next 2Y56.84%
EPS Next 3Y44.95%
EPS Next 5YN/A
Revenue 1Y (TTM)30.7%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%38.34%
Revenue Next Year26%
Revenue Next 2Y21.49%
Revenue Next 3Y19.99%
Revenue Next 5Y17.81%
EBIT growth 1Y-55.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year384.04%
EBIT Next 3Y88.5%
EBIT Next 5Y54.95%
FCF growth 1Y110.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1224.02%
OCF growth 3YN/A
OCF growth 5YN/A
GENIUS SPORTS LTD / GENI FAQ
What is the ChartMill fundamental rating of GENIUS SPORTS LTD (GENI) stock?
ChartMill assigns a fundamental rating of 4 / 10 to GENI.
What is the valuation status of GENIUS SPORTS LTD (GENI) stock?
ChartMill assigns a valuation rating of 1 / 10 to GENIUS SPORTS LTD (GENI). This can be considered as Overvalued.
How profitable is GENIUS SPORTS LTD (GENI) stock?
GENIUS SPORTS LTD (GENI) has a profitability rating of 1 / 10.